Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J 2020, 56. Morrow T. Improving outcomes and managing costs in idiopathic pulmonary fibrosis. Am J ...
Prior studies indicate that pirfenidone and nintedanib use is associated with slowing of lung function deterioration, as well as reduced short-term mortality and reduction in hospital- izations [4–6, 12]. In this large cohort, we observed that only 10% of patients were initiated on an anti-...